Actinium Pharmaceuticals, Inc.
501 Fifth Avenue
New York City
214 articles with Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
The Company also announced the pricing of warrants to purchase up to 42,860,000 shares of common stock at an exercise price of $0.50 per share and with a term of 5 years commencing on the date of issuance.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase additional shares of its common stock in an underwritten public offering.
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 – 4, 2019 in Ottawa, Canada
Studies observed increase in double-stranded DNA breaks and reduction in MCL-1 levels in cell lines resistant to venetoclax following Actimab exposure
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
Actinium's AWE Technology Platform is Being Applied to Generate Antibody Radiation-Conjugates with Select Astellas Targeting Agents
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
Two oral presentations, four poster presentations and panel participation will highlight Actinium's AWE technology platform, clinical programs, next-generation ARC's and the commercial renaissance of radiopharmaceuticals
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
Poster supports rationale for recently initiated Phase 1/2 doublet clinical trial studying novel combination of Actimab-A and venetoclax and planned Phase 1/2 triplet combination trial of Actimab-A and venetoclax with a hypomethylating agent
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
Actinium Pharmaceuticals, Inc. reported its financial results for the fourth quarter and year ended December 31, 2018 as well as provided corporate and operational updates on clinical trials, research and development, recent hires, and intellectual property.
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs.
Broad intellectual property portfolio, know-how, and trade secrets support Actinium's leadership position in Antibody Radiation-Conjugates, Targeted Conditioning and Actinium-225 based therapies
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, being held March 19-20 at the Westin Grand Central Hotel in New York City.
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was reported in a late breaking oral presentation at the 2019 Transplantation & Cellular Therapy Meetings™ of ASBMT and CIBMTR (TCT Meetings) that was held on February 20th – 24th
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
In vivo studies demonstrate CD45 targeting ARC effectively lymphodepletes, allowing cells to expand while sparing bone marrow stem cells, red blood cells and platelets
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
Iomab-B and multiple abstracts selected for inclusion at leading medical conference focused on bone marrow transplant and cellular therapy
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
Iomab-ACT program intended to displace non-specific chemotherapy with targeted, single-dose, outpatient conditioning to improve CAR-T access and outcomes
Combination trial at UCLA Medical Center supported by demonstrated synergy and mechanistic rationale of targeted radiation from Actimab-A with venetoclax in preclinical studies
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin
Combination trial is exploring the potential synergies between targeted internalized radiation via Actimab-A and chemotherapy
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th
Event will also highlight Actinium's recent advances including combination trials with venetoclax, bio-betters and other initiatives enabled by its AWE or Antibody Warhead Enabling technology platform
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) today announced that it will present at NobleConXV - Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 29th at 12:30 pm EST